Chirayu Govind Patel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2025 | 1433 | 2.180 |
Why?
|
| Lymphoma | 5 | 2025 | 1896 | 1.850 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2025 | 1502 | 1.670 |
Why?
|
| Radiotherapy Dosage | 3 | 2025 | 2915 | 0.740 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 1383 | 0.730 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 238 | 0.720 |
Why?
|
| Titanium | 1 | 2023 | 494 | 0.680 |
Why?
|
| Multiple Myeloma | 4 | 2023 | 5186 | 0.670 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 403 | 0.660 |
Why?
|
| Mycosis Fungoides | 2 | 2020 | 169 | 0.650 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 798 | 0.610 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 1372 | 0.560 |
Why?
|
| Leukemia | 1 | 2025 | 1518 | 0.530 |
Why?
|
| Electrons | 1 | 2017 | 264 | 0.500 |
Why?
|
| Education | 1 | 2017 | 531 | 0.460 |
Why?
|
| Scalp | 1 | 2017 | 390 | 0.450 |
Why?
|
| Treatment Refusal | 1 | 2017 | 433 | 0.450 |
Why?
|
| Central Nervous System Diseases | 1 | 2017 | 518 | 0.410 |
Why?
|
| Osteonecrosis | 1 | 2014 | 230 | 0.400 |
Why?
|
| Organs at Risk | 2 | 2025 | 367 | 0.380 |
Why?
|
| Bone Remodeling | 1 | 2014 | 582 | 0.350 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 443 | 0.350 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2025 | 1677 | 0.350 |
Why?
|
| Diphosphonates | 1 | 2014 | 633 | 0.330 |
Why?
|
| Imidazoles | 1 | 2014 | 1169 | 0.300 |
Why?
|
| Protons | 2 | 2023 | 1101 | 0.280 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 797 | 0.270 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2025 | 2028 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5716 | 0.220 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2023 | 148 | 0.200 |
Why?
|
| Fractures, Compression | 1 | 2023 | 132 | 0.190 |
Why?
|
| Humans | 24 | 2025 | 767040 | 0.170 |
Why?
|
| Radiation Pneumonitis | 1 | 2020 | 100 | 0.170 |
Why?
|
| Mediastinum | 1 | 2020 | 272 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2025 | 1271 | 0.150 |
Why?
|
| Radiometry | 1 | 2023 | 818 | 0.140 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 2118 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 1788 | 0.140 |
Why?
|
| Spinal Fractures | 1 | 2023 | 710 | 0.140 |
Why?
|
| Prognosis | 3 | 2025 | 29963 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2023 | 1345 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2025 | 81659 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2020 | 1500 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2568 | 0.110 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 2487 | 0.110 |
Why?
|
| Artifacts | 1 | 2023 | 1904 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2702 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2023 | 10092 | 0.110 |
Why?
|
| Quality of Life | 3 | 2025 | 13485 | 0.100 |
Why?
|
| Neoplasms | 2 | 2019 | 22350 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 11217 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2014 | 617 | 0.090 |
Why?
|
| Middle Aged | 8 | 2025 | 223233 | 0.090 |
Why?
|
| Male | 10 | 2025 | 364203 | 0.090 |
Why?
|
| Survival Rate | 1 | 2025 | 12823 | 0.090 |
Why?
|
| Bone Resorption | 1 | 2014 | 726 | 0.090 |
Why?
|
| Aged | 7 | 2025 | 171319 | 0.090 |
Why?
|
| Palliative Care | 1 | 2025 | 3641 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 5859 | 0.080 |
Why?
|
| Heart | 1 | 2022 | 4429 | 0.080 |
Why?
|
| Adult | 5 | 2025 | 223317 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 39317 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3804 | 0.070 |
Why?
|
| Cause of Death | 1 | 2017 | 3717 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 790 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 8068 | 0.070 |
Why?
|
| Female | 8 | 2025 | 396660 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3552 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9410 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2017 | 3461 | 0.050 |
Why?
|
| Peptides | 1 | 2014 | 4348 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 2186 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 54886 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 65295 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20741 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 7446 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 157 | 0.040 |
Why?
|
| Spine | 1 | 2023 | 1139 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 9108 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2019 | 492 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 36485 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 59980 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 59548 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 1480 | 0.030 |
Why?
|
| Child | 2 | 2020 | 80771 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 89046 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11872 | 0.030 |
Why?
|
| Cystectomy | 1 | 2013 | 603 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 8504 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 1656 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6513 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2900 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3611 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12536 | 0.010 |
Why?
|
| Logistic Models | 1 | 2019 | 13284 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6844 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15925 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 41718 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40154 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 10393 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 74886 | 0.010 |
Why?
|